EUVIMEDEUVIMED entdecken
Crossref

CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients

Sutao Zhou, Xueqing Xu, Juan Cuo, Chao Sun, Yali Hou, Xia Wang, Duan Nana, Shi Weixun

Clinical Laboratory · 2026 · 72 (05/2026)

DOI: 10.7754/clin.lab.2025.250744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Laboratory, 2026. Verfasst von Sutao Zhou und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Multiple Myeloma, Bortezomib, Natural Killer T-Cells, Biomarkers, Tumor.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBortezomibNatural Killer T-CellsBiomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneDrug Resistance, NeoplasmLymphocyte CountT-Lymphocyte SubsetsNK Cell Lectin-Like Receptor Subfamily BCD56 AntigenCD3 ComplexCase-Control StudiesFlow CytometryCell SeparationTumor BurdenROC CurveNeoplasm StagingHumansMaleMiddle AgedAged

Substanzen

BortezomibDexamethasoneKLRB1 protein, humanNK Cell Lectin-Like Receptor Subfamily BBiomarkers, TumorNCAM1 protein, humanCD56 AntigenCD3 Complex

Zitieren

APA

Zhou, S., Xu, X., Cuo, J., Sun, C., Hou, Y., Wang, X., Nana, D., & Weixun, S. (2026). CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients. Clinical Laboratory, 72(05/2026). https://doi.org/10.7754/clin.lab.2025.250744

Vancouver

Zhou S, Xu X, Cuo J, Sun C, Hou Y, Wang X, et al. CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients. Clinical Laboratory. 2026;72(05/2026). doi:10.7754/clin.lab.2025.250744

BibTeX
@article{Zhou2026,
  author = {Zhou, Sutao and Xu, Xueqing and Cuo, Juan and Sun, Chao and Hou, Yali and Wang, Xia and Nana, Duan and Weixun, Shi},
  title = {CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients},
  journal = {Clinical Laboratory},
  year = {2026},
  volume = {72},
  number = {05/2026},
  doi = {10.7754/clin.lab.2025.250744}
}
Kostenlos starten →